“Our goal is to accelerate the Botanical Synthesis movement that our team has wholly dedicated themselves to – driving forward innovation, our...
Read MoreBIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT OF CONVERTIBLE NOTES AND EXPECTS THE OFFERING TO BE OVERSUBSCRIBED AND TO CLOSE AN ADDITIONAL TRANCHE OF UP TO $3 MILLION BY DECEMBER 15, 2022
November 15, 2022
This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.
VANCOUVER, CANADA, and REHOVOT, ISRAEL, NOVEMBER 15, 2022 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is pleased to announce that it has closed the second tranche (the “Second Tranche”) of its non-brokered private placement of convertible notes (the “Notes”) previously announced on October 7, 2022. Due to the significant demand for this offering, the Company expects the offering to be oversubscribed and to close an additional tranche of up to $3 Million CAD by December 15, 2022, subject to regulatory approvals. Under the Second Tranche, the Company has issued Notes in the aggregate principal amount of $2,612,742.28 CAD. With the closing of this tranche the aggregate amount raised under the offering to date is $ 9,490,985.94.
The Notes issued under the Second Tranche, and any Common Shares issuable upon conversion of such Notes, are subject to a four month and one day hold expiring March 16, 2023.
About BioHarvest Sciences Inc.
Based in Vancouver, BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com.
Our Blog
Are depleted soils depleting the benefits of fruits and vegetables?
By Dr. Brian Cornblatt Over the past 50 years there has been a paradigm shift in dietary preferences. The proverbial meat and potatoes —once...
Read MoreAbout BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals – nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API’s) that focus on specific medical indications.
